Processa Pharmaceuticals (PCSA) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free PCSA Stock Alerts $1.88 -0.06 (-3.09%) (As of 01:26 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Processa Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:PCSA)May 15, 2024 | americanbankingnews.comProcessa Pharmaceuticals, Inc. Expected to Post Q1 2025 Earnings of ($0.74) Per Share (NASDAQ:PCSA)May 15, 2024 | americanbankingnews.comProcessa Pharmaceuticals' (PCSA) Buy Rating Reiterated at HC WainwrightMay 6, 2024 | globenewswire.comProcessa Pharmaceuticals to Participate in the EF Hutton Annual Global ConferenceApril 30, 2024 | globenewswire.comProcessa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical ResearchApril 26, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Processa Pharmaceuticals (PCSA) with Buy RecommendationApril 11, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 1.09%April 11, 2024 | finance.yahoo.comProcessa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b TrialApril 7, 2024 | finance.yahoo.comInsider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40kMarch 28, 2024 | nz.finance.yahoo.comEva Mendes says she had 'non-verbal agreement' with Ryan Gosling to be a stay-at-home momMarch 28, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comProcessa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual MeetingFebruary 24, 2024 | msn.comProcessa Pharmaceuticals (PCSA) Price Target Increased by 1900.00% to 81.60February 21, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 21, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 14, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 14, 2024 | globenewswire.comProcessa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceFebruary 6, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleFebruary 6, 2024 | investing.comProcessa Pharmaceuticals Inc (PCSA)February 1, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Closing of $7.0 Million Public OfferingFebruary 1, 2024 | msn.comProcessa Pharmaceuticals Announces Offering Pricing DetailsJanuary 27, 2024 | marketwatch.comProcessa Pharmaceuticals Shares Drop 24% After Pricing OfferingJanuary 26, 2024 | msn.comProcessa Pharmaceuticals prices discounted stock and warrants offering to raise $7MJanuary 26, 2024 | msn.comWhat's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?January 26, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingJanuary 25, 2024 | marketwatch.comProcessa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer TreatmentJanuary 25, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 DosesJanuary 25, 2024 | marketbeat.comTrading was temporarily halted for "PCSA" at 09:01 AM with a stated reason of "LULD pause." Trading set to resume at 09:01 AM. January 22, 2024 | marketbeat.comTrading was temporarily halted for "PCSA" at 07:01 PM with a stated reason of "News pending."January 20, 2024 | msn.comProcessa Pharmaceuticals Expands NGC-Cap Cancer ProgramJanuary 19, 2024 | finanznachrichten.deProcessa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerJanuary 19, 2024 | msn.comWhy Processa Pharmaceuticals (PCSA) Stock Is SkyrocketingJanuary 19, 2024 | finance.yahoo.comProcessa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerJanuary 18, 2024 | finanznachrichten.deProcessa Pharmaceuticals, Inc.: Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock SplitJanuary 18, 2024 | msn.comWhy Processa Pharmaceuticals (PCSA) Shares Are NosedivingJanuary 18, 2024 | msn.comProcessa Pharmaceuticals to effect 1-for-20 reverse stock split to regain compliance with Nasdaq ruleJanuary 18, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Effect a 1-for-20 Reverse Stock SplitJanuary 2, 2024 | finance.yahoo.comProcessa Pharmaceuticals to Present at the Biotech Showcase 2024December 19, 2023 | finance.yahoo.comProcessa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over CapecitabineDecember 13, 2023 | msn.comWhat's Going On With Processa Pharmaceuticals (PCSA) Stock?December 12, 2023 | finance.yahoo.comIs Processa Pharmaceuticals (NASDAQ:PCSA) In A Good Position To Invest In Growth?November 30, 2023 | finance.yahoo.comProcessa Pharmaceuticals to Present at the MedInvest Oncology Investor ConferenceNovember 29, 2023 | finance.yahoo.comProcessa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and OutlookNovember 21, 2023 | morningstar.comProcessa Pharmaceuticals Inc PCSANovember 18, 2023 | msn.comMaxim Group Downgrades Processa Pharmaceuticals (PCSA)November 17, 2023 | realmoney.thestreet.comProcessa Pharmaceuticals downgraded to Hold from Buy at MaximNovember 13, 2023 | finance.yahoo.comProcessa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil ThompsonNovember 9, 2023 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 AmericasSeptember 17, 2023 | barrons.comProcessa Pharmaceuticals Inc.September 6, 2023 | finance.yahoo.comProcessa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. PCSA Media Mentions By Week PCSA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCSA News Sentiment▼0.360.43▲Average Medical News Sentiment PCSA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCSA Articles This Week▼91▲PCSA Articles Average Week Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Xenetic Biosciences News Hillstream BioPharma News First Wave BioPharma News Enveric Biosciences News Ainos News Lixte Biotechnology News ASLAN Pharmaceuticals News Pulmatrix News Biofrontera News Kineta News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCSA) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss Ratings4 Cryptos BETTER than BitcoinTrue Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
